GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

vatiquinone   Click here for help

GtoPdb Ligand ID: 14277

Synonyms: alpha-Tocotrienol quinone [3] | ATQ3 | EPI-743 | EPI743 | PTC-743 | PTC743
Compound class: Synthetic organic
Comment: Vatiquinone (EPI-743; PTC-743) is an arachidonate 15-lipoxygenase (ALOX15) inhibitor [1]. It is orally bioavailable and crosses the blood-brain barrier.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 3
Hydrogen bond donors 1
Rotatable bonds 12
Topological polar surface area 54.37
Molecular weight 440.66
XLogP 6.21
No. Lipinski's rules broken 2

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CC(=CCC/C(=C/CC/C(=C/CC[C@](C)(CCC1=C(C)C(=O)C(=C(C)C1=O)C)O)/C)/C)C
Isomeric SMILES CC1=C(C(=O)C(=C(C1=O)C)CC[C@@](C)(CC/C=C(\C)/CC/C=C(\C)/CCC=C(C)C)O)C
InChI InChI=1S/C29H44O3/c1-20(2)12-9-13-21(3)14-10-15-22(4)16-11-18-29(8,32)19-17-26-25(7)27(30)23(5)24(6)28(26)31/h12,14,16,32H,9-11,13,15,17-19H2,1-8H3/b21-14+,22-16+/t29-/m1/s1
InChI Key LNOVHERIIMJMDG-XZXLULOTSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

No information available.
Summary of Clinical Use Click here for help
Vatiquinone (EPI-743) was developed as a potential therapeutic for inherited respiratory chain mitochondrial diseases [1-2].
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT01721733 Safety and Efficacy Study of EPI-743 in Children With Leigh Syndrome Phase 2 Interventional PTC Therapeutics
NCT01822249 Phase 2 Study of EPI-743 for Treatment of Rett Syndrome Phase 2 Interventional Edison Pharmaceuticals Inc
NCT05515536 A Study to Assess the Safety and Efficacy of Vatiquinone in Participants With Friedreich Ataxia Phase 3 Interventional PTC Therapeutics
NCT05218655 A Safety Study for Previously Treated Vatiquinone (PTC743) Participants With Inherited Mitochondrial Disease Phase 3 Interventional PTC Therapeutics